Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:RAIN

Rain Oncology (RAIN) Stock Price, News & Analysis

Rain Oncology logo

About Rain Oncology Stock (NASDAQ:RAIN)

Advanced Chart

Key Stats

Today's Range
$4.29
$4.60
50-Day Range
$1.20
$1.24
52-Week Range
$0.82
$11.32
Volume
11,637 shs
Average Volume
32,376 shs
Market Capitalization
$24.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

As of January 26, 2024, operates as a subsidiary of Pathos AI, Inc.

Receive RAIN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rain Oncology and its competitors with MarketBeat's FREE daily newsletter.

RAIN Stock News Headlines

Missed Nvidia? Trump’s Trade War Could Create a Bigger Winner
Missed out on Nvidia? Don’t worry — a bigger AI opportunity may be emerging right now, thanks to Trump’s newly announced tariffs. One under-the-radar U.S. semiconductor stock just gained a major edge over its foreign rivals. With demand poised to skyrocket, this chipmaker could be perfectly positioned to ride the next wave of AI growth. Shares are still flying low — but not for long.
See More Headlines

RAIN Stock Analysis - Frequently Asked Questions

Rain Oncology Inc. (NASDAQ:RAIN) released its quarterly earnings data on Thursday, May, 15th. The company reported ($0.20) earnings per share for the quarter.

Rain Oncology (RAIN) raised $126 million in an initial public offering (IPO) on Friday, April 23rd 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. Goldman Sachs, Citigroup, Piper Sandler and Guggenheim Securities acted as the underwriters for the IPO.

Top institutional shareholders of Rain Oncology include Polar Asset Management Partners Inc. (0.52%) and Apollo Management Holdings L.P. (0.43%). Insiders that own company stock include Bvf Partners L P/Il, Boxer Capital, Llc, Franklin M Berger and Paul T Dacier.
View institutional ownership trends
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Rain Oncology investors own include CRISPR Therapeutics (CRSP), Meta Platforms (META), UiPath (PATH), Recursion Pharmaceuticals (RXRX), Alibaba Group (BABA), NVIDIA (NVDA) and

Company Calendar

Last Earnings
5/15/2025
Today
5/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Holding & other investment offices
Sub-Industry
N/A
Current Symbol
NASDAQ:RAIN
Fax
N/A
Employees
63
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$3.10 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
$0.60 per share
Price / Cash Flow
7.41
Book Value
($0.69) per share
Price / Book
-6.45

Miscellaneous

Free Float
4,574,000
Market Cap
$24.65 million
Optionable
No Data
Beta
-0.11
10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:RAIN) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners